# Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

> **NCT00698061** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 145 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** HBV-MPL vaccine 208129
- **BIOLOGICAL:** Engerix™-B

## Key facts

- **NCT ID:** NCT00698061
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-11
- **Primary completion:** 2000-09
- **Final completion:** 2001-05
- **Target enrollment:** 145 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00698061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00698061, "Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00698061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*